SCHEMBL3544289

SCHEMBL3544289

CC(=O)N1CCN(c2ncc(NC(=O)C(=O)O)cn2)CC1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PTPN11 Q06124 1/20 0.52
GAA P10253 1/20 0.45
MAPT P10636 3/20 0.44
MEN1 O00255 2/20 0.44
KMT2A Q03164 2/20 0.44
HDAC3 O15379 1/20 0.43
HDAC4 P56524 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC2 Q92769 1/20 0.43
HDAC10 Q969S8 1/20 0.43
HDAC11 Q96DB2 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
HDAC9 Q9UKV0 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
PANK3 Q9H999 1/20 0.43
NPC1 O15118 1/20 0.42
RAB9A P51151 1/20 0.42
ACHE P22303 3/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13009501 0.86 PTPN11 (0.47) PTPN11GAAMAPTMEN1KMT2A
SCHEMBL19283660 0.79 OGA (0.51) PTPN11GAAMAPTMEN1KMT2A
SCHEMBL12457514 0.77 MEN1 (0.51) PTPN11MAPTMEN1KMT2AHDAC3
SCHEMBL4516986 0.77 MAPT (0.75) GAAMAPTMEN1KMT2ANPC1
SCHEMBL1433484 0.75 PANK3 (0.54) PTPN11MAPTMEN1KMT2AHDAC3
SCHEMBL23969474 0.74 RORC (0.50) PTPN11MAPTMEN1KMT2AHDAC3
SCHEMBL1919434 0.73 MEN1 (0.73) GAAMEN1KMT2ANPC1RAB9A
SCHEMBL19105531 0.73 PANK3 (0.52) PTPN11GAAMAPTMEN1KMT2A
SCHEMBL12701278 0.73 MEN1 (0.48) PTPN11MAPTMEN1KMT2AHDAC3
SCHEMBL23571193 0.73 MEN1 (0.48) PTPN11GAAMAPTMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS ASTRAZENECA AB (SE) 2010-12-16 US disclosed
US-7795283-B2 Oxadiazole derivative as DGAT inhibitors ASTRAZENECA AB (SE) 2010-09-14 US disclosed
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors ASTRAZENECA AB (SE) 2008-04-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100317653-A1 OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS DGAT1, DGAT2, GPR119 PTPN11 3606/4885GAA 171/4885MAPT 2115/4885
US-20080096874-A1 Oxadiazole Derivative as Dgat Inhibitors DGAT1, DGAT2, GPR119 PTPN11 3612/4885GAA 163/4885MAPT 1986/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.